Abstract: The present invention relates to crystalline compounds comprising vadadustat and L-proline and processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one or more of the crystalline compounds of the present invention and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of anemia for example in patients with end-stage renal disease (ESRD) and/or chronic kidney disease (CKD).

Abstract: A deep-drawing arrangement is for deep-drawing a continuously supplied film strip. The deep-drawing arrangement includes a transporter which revolves continuously around a fixed machine frame and which has plate elements and mold cavities and a cyclically timed deep-drawing apparatus, wherein the mold cavities can be acted on with a pressure reduction. The plate elements are permanently connected to each other via connection lines. A plate element is in the form of a connection element having at least one pressure reduction connection. The pressure reduction connection is connected to a pressure reduction source. The plate elements are permanently acted on with the pressure reduction during operation via the connection lines and the pressure reduction connection. Each plate element has at least one switching valve for connecting the pressure reduction which is permanently applied in the plate element to the associated mold cavities as required.

Abstract: The present invention relates to crystalline forms of cabotegravir sodium and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one of said crystalline forms of cabotegravir sodium, preferably in a predetermined and/or effective amount, and at last one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prophylaxis of viral infections such as HIV infections.

Abstract: An apparatus and a method are for sealing packages on a flatbed machine. The package is formed from a base-film web and a water-soluble cover-film web. The sealing apparatus includes a liquid supply, at least one moistening unit, and a pressing device for vertically pressing and sealing the cover-film web together with the base-film web. The moistening unit has a moistening roller and a spraying device, the moistening unit being able to be switched between a first operating state and a second operating state. In the first operating state, the moistening roller acts on the cover-film web at a roller moistening location. During or after a machine standstill period, the sealing apparatus is transferred to a second operating state in which the spraying device acts on a spray portion of the cover-film web. The spray portion lies between the roller moistening location and the sealing location in the feed region.

Abstract: An apparatus and a method are for sealing packages on a flatbed machine. The package is formed from a base-film web and a water-soluble cover-film web. The sealing apparatus includes a liquid supply, at least one moistening unit, and a pressing device for vertically pressing and sealing the cover-film web together with the base-film web. The moistening unit has a moistening roller and a spraying device, the moistening unit being able to be switched between a first operating state and a second operating state. In the first operating state, the moistening roller acts on the cover-film web at a roller moistening location. During or after a machine standstill period, the sealing apparatus is transferred to a second operating state in which the spraying device acts on a spray portion of the cover-film web. The spray portion lies between the roller moistening location and the sealing location in the feed region.

Abstract: The present invention relates to crystalline avapritinib, polymorphs and hydrates thereof as well as to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising crystalline avapritinib and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of patients with gastrointestinal stromal tumors (GIST) and advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL).

Abstract: The present invention relates to crystalline compounds comprising vadadustat and L-proline and processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one or more of the crystalline compounds of the present invention and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of anemia for example in patients with end-stage renal disease (ESRD) and/or chronic kidney disease (CKD).

Abstract: A deep-drawing apparatus includes an arrangement of die plates, wherein each die plate has a plurality of frame vacuum holes and at least one female die having at least one die vacuum hole. At least one vacuum channel connects a vacuum source to the die vacuum hole of the female die and to the frame vacuum holes of the die plate. The deep-drawing apparatus includes for each die plate a closing device for closing and opening the vacuum channel. The die plate is fed a single foil sheet. The closing device opens the connecting channel at the corresponding die plate and the foil sheet is laid onto the die plate. Thereafter, the foil is held on the frame vacuum holes by a holding vacuum and is deep-drawn by a deep-drawing vacuum at the die vacuum holes in the female die. A method for the deep-drawing of foil is also disclosed.

Abstract: The present invention relates to crystalline forms of cabotegravir sodium and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one of said crystalline forms of cabotegravir sodium, preferably in a predetermined and/or effective amount, and at last one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prophylaxis of viral infections such as HIV infections.

Abstract: The present invention relates to crystalline forms of cabotegravir sodium and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one of said crystalline forms of cabotegravir sodium, preferably in a predetermined and/or effective amount, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prophylaxis of viral infections such as HIV infections.

Abstract: The present invention relates to a crystalline form of darolutamide and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline form of darolutamide, preferably in a predetermined and/or effective amount, and at least one pharmaceutically acceptable excipient. The present invention also relates to 5 pharmaceutical compositions comprising darolutamide at a high drug load. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of prostate cancer.

Abstract: The present invention relates to crystalline forms of cabotegravir sodium and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one of said crystalline forms of cabotegravir sodium, preferably in a predetermined and/or effective amount, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prophylaxis of viral infections such as HIV infections.

Abstract: A deep-drawing apparatus includes an arrangement of die plates, wherein each die plate has a plurality of frame vacuum holes and at least one female die having at least one die vacuum hole. At least one vacuum channel connects a vacuum source to the die vacuum hole of the female die and to the frame vacuum holes of the die plate. The deep-drawing apparatus includes for each die plate a closing device for closing and opening the vacuum channel. The die plate is fed a single foil sheet. The closing device opens the connecting channel at the corresponding die plate and the foil sheet is laid onto the die plate. Thereafter, the foil is held on the frame vacuum holes by a holding vacuum and is deep-drawn by a deep-drawing vacuum at the die vacuum holes in the female die. A method for the deep-drawing of foil is also disclosed.

Abstract: The invention relates to novel hydrates of dolutegravir sodium and to processes for their preparation. Furthermore, the invention relates to a novel crystalline form of dolutegravir sodium, which is a useful intermediate for the preparation of one of the novel hydrates. In addition, the invention relates to the use of the novel hydrates for the production of pharmaceutical compositions. Finally, the invention relates to pharmaceutical compositions comprising an effective amount of the novel hydrates, to oral dosage forms comprising said pharmaceutical compositions, to a process for preparing said oral dosage forms, and to the use of said pharmaceutical compositions or dosage forms in the treatment of retroviral infections such as HIV-1 infections.

Abstract: The invention relates to novel hydrates of dolutegravir sodium and to processes for their preparation. Furthermore, the invention relates to a novel crystalline form of dolutegravir sodium, which is a useful intermediate for the preparation of one of the novel hydrates. In addition, the invention relates to the use of the novel hydrates for the production of pharmaceutical compositions. Finally, the invention relates to pharmaceutical compositions comprising an effective amount of the novel hydrates, to oral dosage forms comprising said pharmaceutical compositions, to a process for preparing said oral dosage forms, and to the use of said pharmaceutical compositions or dosage forms in the treatment of retroviral infections such as HIV-1 infections.